<DOC>
	<DOC>NCT01094093</DOC>
	<brief_summary>The purpose of this study is to assess the safety and tolerability of AMG 139 following single subcutaneous (SC) or intravenous (IV) dose administration in healthy subjects and subjects with moderate to severe psoriasis (PsO).</brief_summary>
	<brief_title>Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 139 in Healthy Subjects and Subjects With Moderate to Severe Psoriasis</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<criteria>Part A Healthy Volunteers: Healthy male or female of nonreproductive potential subjects between 18 to 45 yearsofage Body mass index (BMI) between 18 and 32 kg/m2 Normal or clinically acceptable physical examination, clinical laboratory values, and ECG Additional inclusion criteria apply Part B Psoriasis Subjects: Male or female of nonreproductive potential subjects with PsO between 18 to 55 yearsofage Body mass index (BMI) between 18 and 32 kg/m2 Normal or clinically acceptable physical examination (PE), clinical laboratory values, and ECG; clinically acceptable PE includes evidence of moderate to severe plaque PsO Diagnosis of plaque PsO for at least 6 months Moderate to severe plaque PsO defined by: A minimum PASI score of ≥ 10 Psoriasis involving ≥ 10% of the Body Surface Area (BSA) Additional inclusion criteria apply Parts A Healthy Volunteers: History or evidence of a clinically significant disorder (including psychiatric), condition or disease that would pose a risk to subject safety or interfere with the study evaluation, procedures or completion; Recent or ongoing infection(s) Underlying condition(s) that predisposes the subject to infections History of malignancy of any type, other than in situ cervical cancer or surgically excised nonmelanomatous skin cancers in past 5 years Additional exclusion criteria apply Part B Psoriasis Subjects: History or evidence of a clinically significant disorder (including psychiatric), condition or disease that would pose a risk to subject safety or interfere with the study evaluation, procedures or completion; Recent or ongoing infection(s) Underlying condition(s) that predisposes the subject to infections Guttate, pustular, or other nonplaque forms of PsO Evidence of skin conditions other than PsO (eg, eczema) that would interfere with evaluations of the effect of investigational product on psoriasis History of malignancy of any type, other than in situ cervical cancer or surgically excised nonmelanomatous skin cancers in past 5 years Additional exclusion criteria apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>September 2011</verification_date>
	<keyword>Amgen</keyword>
	<keyword>AMG 139</keyword>
</DOC>